The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The Grail, NHS collaboration just shows how much you need a big pharma in this business, something AN has always resisted.
It also begs the question, if parsortex is great why hasn't the likes of Grail brought it for the said trial? God knows it's cheap enough.
No, I have written off my money with Angle. My hopes for the future are gone and yes I know I should have sold sooner but that what blind faith will get you ... disapointment. .. I have no one to blame but myself . Sad day
Bermuda ... Great Post. ...
I would suggest you put that on SK's board in ADVFM as there are a few posters ( put politely ) on there that need reminding of what this is all about. Sadly, I don't think it will make a scape of difference to them. ( Well not until they need it)
I have deliberately not looked at the share price or this board for a while so forgive me if this has been said before recently.
I don't want to hear any reasons for or against why the SP is what is it. I just want to make the following points.
.
1 ... There are no new shares to buy.
2 ... The only shares available are from existing holders selling (Go figure.)
3 ... Every share that has become available has been snapped up by the end of the day.
4 ... This is a very popular share.
.
In any legitimate market, all the above would send the price up. No excuses.
This is fast becoming worthy of a criminal investigation. MM = Mafia mod.
Further to Boonco's point, it's worth pointing out at Angle does hold an ISO certificate, ( ISO 13485:2016 & EN ISO 13845:2016 )
Though quite what this means and what weight it carries with the FDA is beyond my knowledge.
Miavoce and Researcher, Thank you both for clearing that up. That is what I thought before the question came into my head.
As you said, it's not worth sweating over, I mean it's not like I'm going to sell any time soon.
Thanks again.
Miavoce, while I totally agree with you on Angles application being solely for one type of cancer as far as the FDA is concerned, this kind of presents me with a dilemma. People talk about the weight of averdence from other research body's regarding Parsortix's many other uses as having an influence on their decision when it comes to this application, which is for MBC only. As this is a denovo application my dilemma is this. Are they looking at it's ability to capture cancer cells in general, in which case the averdence from other cancer research is relevant. Or are are we going to have to submit separate denovo applications for each cancer type. I am unclear as to what the denovo part of the application refers to. I would appreciate your help in solving this catch 22 problem which has been going round in my head for sometime.
Whilst I understand that sentiment and speculation have a huge part to play in determining the price, surely, with purchases out numbering sales by a factor of 2 to 1, what's happened to the old market rule of supply and demand.
.... Too naive ?